Monday, January 04, 2021 9:34:41 AM
December 10, 2020 01:19 PM ET (BZ Newswire) -- Biotech
Dyadic International. Inc. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020.
With the world eager to get the COVID-19 pandemic under control, the search for both vaccines and treatments has become a priority.
The virus continues to wreak havoc around the world, affecting every aspect of life. Unemployment is sky-high, economies are teetering on depression, and the common fear of the disease delays the return to life as we once knew it.
That is why many different companies and ventures are helping to find a solution to the global health emergency. Yet, we will require a massive production of vaccines at a low cost to distribute it affordably on a global basis. Thus, this desperate need for faster, cheaper biologic production pushes governments to pursue solutions apart from the private sector.
Dyadic International, Inc. (NASDAQ:DYAI) is a commercially proven gene expression company that has its roots in industrial biotechnology. The U.S., the EU, Israel, and other countries, government organizations, pharmaceutical, and biotech companies are collaborating with the company to find a possible solution and develop both the SARS-CoV-2 vaccine candidates and treatment through monoclonal antibodies.
Dyadic’s Gene Expression Systems
The COVID-19 pandemic has shed light on the pharmaceutical industry’s needs, governments, and citizens to evaluate disruptions in the manufacturing of biologic vaccines and drugs. Here’s where biotechnology such as Dyadic’s C1 comes to play a key role in COVID-19’s pharmaceutical response.
The company’s C1 Gene Expression platform has been re-engineered and can be used to manufacture biologic vaccines and drugs for years to come at more cost-effective and rapid speeds. The company aims to respond to the need for a COVID-19 vaccine by driving the adoption of its C1 platform.
Dyadic discovered a unique and highly expressive fungal host through their work in developing a gene expression system for producing enzymes used for a variety of industrial uses including biofuels. These discoveries and improvements led the company’s C1 Gene Expression Platform. Over the years, C1 has gained recognition in industrial biotechnology, winning business with customers and licensees such as Abengoa S.A. (NASDAQ:ABGOF), du Pont (NYSE:DD), BASF SE (NASDAQ:BFFAF), and Royal Dutch Shell Plc (NASDAQ:RYDAF).
Over the past two decades, C1 technology has been developed into a next-generation protein expression. C1’s ability to produce high-quality enzymes at high yields and purity made the C1 technology a well-regarded expression platform used in many industrial applications. All of this led to the sale of Dyadic’s Industrial Biotechnology business to DuPont back in December 2015 for $75 million.
Dyadic And ZAPI: Research And Collaboration
Back in 2015, the EU funded the IMI Zoonotic Anticipation Preparedness Initiative (ZAPI). Through it, several well-known production platforms were extensively evaluated and only Dyadic’s C1 gene expression platform was chosen as the ideal cell line that could rapidly produce difficult to express antigens at low costs and in large amounts to help protect against potential outbreaks. The company developed the SARS-CoV-2 RBD vaccine candidate in collaboration with the IIBR and three of the top coronavirus scientists from ZAPI.
Through this collaboration, which started earlier this year when the pandemic surfaced, a stable C1 cell line was rapidly generated. The results demonstrated that the C1 SARS-CoV-2 could be one of the most successful vaccine producers against COVID-19 since it enables rapid low-cost production of potentially billions of vaccine doses. Its C1 technology has been designed to be compatible with existing manufacturing facilities globally.
The Quest For A Solution
In addition to vaccines, C1 has the potential to produce monoclonal antibodies (mAbs) in high amounts more rapidly than using CHO (Chinese Hamster Ovaries) cells or other production methods. This allows for more rapid manufacturing of greater amounts of lower-cost mAbs to treat diseases including COVID-19.
European governments, Israel, and now the United States are all working with C1 to accelerate their vaccine development programs. Up to 10 global animal trials are to be completed by early Q1 of 2021 making it a total of 9 different parties using Dyadic’s COVID-19 vaccine candidates. Samples have been sent to Frederick National Laboratories for their evaluation. A SARS-CoV-2 monoclonal antibody (mAb) in collaboration with IDBiologics Inc has been expressed. Dyadic is also in discussions with other parties to express additional COVID-19 mAbs, vaccines, and diagnostics proteins.
To learn more about Dyadic, click here.
Photo by National Cancer Institute on Unsplash
Copyright © 2021 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved.
Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com). ;
Recent DYAI News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:15:54 PM
- Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 07/30/2024 08:00:00 PM
- Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership • GlobeNewswire Inc. • 06/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 01:26:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:31:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:36:45 PM
- Dyadic to Attend Industry Events in June • GlobeNewswire Inc. • 05/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 07:42:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:47:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:30 PM
- Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/14/2024 08:00:00 PM
- Dyadic to Attend Industry and Investor Events in May • GlobeNewswire Inc. • 05/08/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/08/2024 04:15:21 AM
- Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:30:00 PM
- Dyadic Reports 2023 Full Year Results and Recent Company Progress • GlobeNewswire Inc. • 03/28/2024 08:00:00 PM
- Dyadic Announces Change in Board and Management Leadership Roles • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Dyadic to Attend Industry Events in April • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/14/2024 08:30:00 PM
- CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 01:57:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:45:28 PM
- Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM